Getting the right data to doctors is next hurdle for precision medicine
The future of precision medicine will come only as quickly as doctors can pick out clinically useful information from the genetic data being gathered on their patients.
The future of precision medicine will come only as quickly as doctors can pick out clinically useful information from the genetic data being gathered on their patients.
AltheaDx has raised significant funds to further its personalized medicine platform led by WuXi Healthcare Ventures.
Gianrico Farrugia keynoted this week's Individualizing Medicine Conference at Mayo Clinic with a talk on what to expect in the immediate future of precision medicine.
Susan Hertzberg, Boston Heart Diagnostics CEO said although genomic sequencing holds a lot of promise beyond cancer treatment, "right here, right now, we have not optimized or used fully what's available."
In a further sign of the convergence happening in healthcare technology, genomics company GuardantHealth is teaming with health IT and analytics vendor Flatiron Health to create a new platform to enable personalized cancer care.
While advances in care will extend the life of people, the impact of this shift on society may be dramatic.
A new report from Relatient, A Data-Driven Guide to Patient Access Succes, highlights how focusing on data accuracy and relevance can enhance the performance of healthcare practices.
While it's challenging to keep up to date with all the news in precision medicine, Twitter's a good place to get a constant stream of good information - if you know where to look. These Twitter users know a thing or two about precision medicine.
In a joint press release, NantHealth and Allscripts said that they would jointly integrate their software via application provider interfaces
"We basically have a medical community that doesn't embrace the use of genomics," Dr. Eric Topol said. "Often times these days, it's the patients that are clamoring."
Accenture has come out with its annual list of trends in health IT, and it's safe to say the research and consulting firm is looking far beyond Meaningful Use.
Zelis CEO Amanda Eisel shares her perspective on how the company is solving the problems of a fragmented health financial system to benefit all.
As we reported earlier, Dr. Patrick Soon-Shiong keynoted at the American Telemedicine Association’s annual meeting this past week. I also got a chance to meet with him for just a few minutes after his talk, and recorded the interview. In this recording, Soon-Shiong, the billionaire founder of NantWorks and NantHealth, expressed the belief that patients need to be more […]
President Obama proposes that drug manufacturers and Medicare officials work together on drug prices to make precision medicine a more realistic option for beneficiaries.
Is it the president's new initiative? The big investments out of JP Morgan? Or, most recently, the breakthrough decision by the FDA around 23andMe and other genetic testing kits. It's not about whether personalized medicine has arrived. It's here. Now it's about not getting lost in the hype and focusing on what matters.
23andMe can offer genetic-testing services again after the U.S. Food and Drug Administration said the California company can sell a kit to test for Bloom Syndrome, an obscure affliction that occurs when the altered gene is carried by both patents. This is a crack-in-the-dam moment – not just for 23andMe, which has been out of […]
What’s the best thing about Obama’s new, $215 million precision medicine initiative? While a database of genomic and phenotypic data is great, it’s really all about buzz that could be transformative for biological research – and for business. Just like the 2013 BRAIN Initiative worth $100 million (a scant sum, really, when it comes to […]